Recent Content by Bill_St

It should be recognised that 2/3rds of PWD - Both T1 and T2 - are Overweight or Obese. Unfortunately the stigma of weight combines with stigma of D and we hear too little about the issue. Great that an increasing number can get some help with medications, Terzepatide (Mounjaro) can help reduce...

It should be recognised that 2/3rds of PWD - Both T1 and T2 - are Overweight or Obese. Unfortunately the stigma of weight combines with stigma of D and we hear too little about the issue. Great that an increasing number can get some help with medications, Terzepatide (Mounjaro) can help reduce...

It depends upon where you are. Prescription rates per 1000 patients vary enormously but are rapidly increasing

Mounjaro certainly is available on the NHS but with very strict criteria. Some GPs are prescribing but sometimes need support from a specialist. Prescription rates are continually increasing but it very much depends upon region and individual GP. Rates are generally quite low - fewer than 1% of...

A map is also available. Shows a disturbing comparison between high deprivation/low prescription (eg North Tyneside, 89 items) and low deprivation/wealth. (Eg Kent, over 8,000 items) It would also be interesting to compare with Obesity figures in each region….

Openprescribing.net even allows you to compare practices but it does take some time for the amounts to filter through https://openprescribing.net/analyse/#org=practice&orgIds=00L&numIds=0601023AZBB&denom=nothing&selectedTab=summary

It is interesting to see that some areas do place greater weight on NHS prescription of Mounjaro.

Please read the first post in this thread - with the link at its end. And https://www.researchgate.net/publication/389941221_Cardiovascular_and_Renal_Biomarkers_in_Overweight_and_Obese_Adults_with_Type_1_Diabetes_Treated_with_Tirzepatide_for_21_Months Also the very study that you quote and link...

“Our study shows that obesity rates in adults with type 1 diabetes are increasing and mirror the rates in the general adult population” … your study gives proportion who are Obese. More people are Overweight than Obese. So if ‘only’ 37% are obese, it is easy to see that the proportion of both...

I spend 6 mths a year in Spain where my GP diagnoses me as T1; she is also a diabetes specialist at the local university hospital - very lucky to have her to provide GP services. In the UK I am diagnosed as T2. That has advantages. I was prescribed MJ in Spain and that was used to justify...

The second (slightly larger) study linked gives more detail, with some exceptional significance levels tabulated at the end (p- values) “Tirzepatide users significantly decreased their TDD (−38 ± 5.2 units/day) after 21 months, whereas controls decreased their total daily dose by a...

BMJ recommendations https://www.medscape.com/viewarticle/new-type-2-diabetes-guidance-ties-treatment-choice-cardio-2025a1000m8m?ecd=a2a “SGLT2 inhibitors and GLP-1 RAs, along with finerenone, a nonsteroidal selective mineralocorticoid RA, and tirzepatide, a dual glucose-dependent insulinotropic...

Cannot confirm that all UK sold FSL2+ are manufactured in IR. Some may still be manufactured in Oxon. The stats are as reliable as possible but some reporting must be suspect, such as one I read that claimed the sensor caught Fire! Comparable numbers between Abbott and Dexcom for Loss of...

I must admit that I am still using FSL2. I wished to give time for the new Ireland plant to settle in. https://www.abbott.com/corpnewsroom/strategy-and-strength/abbott-opens-new-facility-to-meet-demand-for-diabetes-technology.html. I have almost no failures over the 10yrs continuous use of Libre...

Libre takes readings every minute. These are used to produce the Spot readings that provide the instant readings you see and the alarms. As can be seen in the chart below, these vary quite considerably. For the chart and all averages, they are first Smoothed. The smoothed line is the chart you...